Zobrazeno 1 - 10
of 7 950
pro vyhledávání: '"ICI"'
Publikováno v:
Akzo Nobel India Limited MarketLine Company Profile. 11/20/2023, p1-17. 17p.
Publikováno v:
Akzo Nobel India Limited MarketLine Company Profile. 10/8/2022, p1-19. 19p.
Publikováno v:
Akzo Nobel India Limited MarketLine Company Profile. 10/20/2021, p1-18. 18p.
Autor:
BAILLY, GARANCE
Publikováno v:
Stratégies. 3/14/2024, Issue 2211, p36-37. 2p.
Publikováno v:
Akzo Nobel India Limited MarketLine Company Profile. 11/2/2020, p1-18. 18p.
Autor:
Jieli Tong, Nikolaos Vogiatzakis, Maria Sol Andres, Isabelle Senechal, Ahmed Badr, Sivatharshini Ramalingam, Stuart D. Rosen, Alexander R. Lyon, Muhummad Sohaib Nazir
Publikováno v:
Cardio-Oncology, Vol 10, Iss 1, Pp 1-8 (2024)
Abstract Background Immune checkpoint inhibitor (ICI) myocarditis is an uncommon but potentially fatal complication of immunotherapy. Cardiac imaging is essential to make timely diagnoses as there are critical downstream implications for patients. Ob
Externí odkaz:
https://doaj.org/article/2cf71d483b3f41c0956ad73da6480d7f
Publikováno v:
Akzo Nobel India Limited MarketLine Company Profile. 9/12/2019, p1-20. 20p.
Publikováno v:
Scientific Reports, Vol 14, Iss 1, Pp 1-17 (2024)
Abstract Bladder urothelial carcinoma (BLCA) presents a persistent challenge in clinical management. Despite recent advancements demonstrating the BLCA efficacy of immune checkpoint inhibitors (ICI) in BLCA patients, there remains a critical need to
Externí odkaz:
https://doaj.org/article/8eac36611cad4b67aef128b7e2866267
Autor:
Jun Yamada, Takafumi Fukui, Atsuhiko Yatani, Chihiro Mimura, Kiyoko Fukuda, Daisuke Hazama, Naoko Katsurada, Tatsuya Nagano, Masatsugu Yamamoto, Motoko Tachihara
Publikováno v:
Thoracic Cancer, Vol 15, Iss 15, Pp 1228-1236 (2024)
Abstract Background There have been reports on the impact of concurrent drugs on the outcome of immunotherapy for non‐small cell lung carcinoma (NSCLC). However, the effect of some drugs, such as antibiotics and nonsteroidal anti‐inflammatory dru
Externí odkaz:
https://doaj.org/article/fae5a8a3540446dcb232bf4125fe27be
Publikováno v:
Journal of Immunotherapy and Precision Oncology, Vol 7, Iss 2, Pp 97-110 (2024)
Abstract: Glioblastoma (GBM) is the most prevalent malignant tumor of the central nervous system. The prognosis of GBM is grim, with a median overall survival of 14.6 months and only 6.9% of patients surviving 5 years after the initial diagnosis. Des
Externí odkaz:
https://doaj.org/article/3cfd5e6154b74787b96b4d64d9a84ea8